



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Baichwal et al.

Serial No. 09/758,003

Filed: January 9, 2001

For: *RIP: Novel Human Protein Involved in Tumor Necrosis Factor Signal Transduction*

Group Art Unit: 1645

Examiner: Not yet assigned

Attorney Docket No. T95-006-2

CERTIFICATE OF MAILING

I hereby certify that this corr. is being deposited with the US Postal Service as First Class Mail in an envelope addressed to the Comm for Patents, Washington, D.C. 20231 on November 6, 2001

Signed

Richard Osman

RESPONSE TO NOTICE TO COMPLY

The Commissioner for Patents  
Washington, DC 20231

Dear Commissioner:

In response to the Notice mailed October 30, 2001, enclosed please find:

-Copy of Notice

-A copy of our previously submitted Request to use CRF from another application which does include the statement that the sequence information on the written Sequence Listing is identical to that recorded in computer readable form requested to be used from the prior application and includes no new matter.

This submission introduces no new matter.

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUP

Richard Aron Osman, Ph.D., Reg. No. 36,627  
Tel: (650) 343-4341; Fax: (650) 343-4342

RECEIVED

JAN 17 2002

OFFICE OF PETITIONS



UNITED STATES PATENT AND TRADEMARK OFFICE

TECHNOLOGY  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/758,003	01/09/2001	Vijay R. Baichwal	T95-006-2

23379  
RICHARD ARON OSMAN  
SCIENCE AND TECHNOLOGY LAW GROUP  
75 DENISE DRIVE  
HILLSBOROUGH, CA 94010

CONFIRMATION NO. 8531

FORMALITIES LETTER



\*OC000000006995943\*

Date Mailed: 10/30/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED  
JAN 17 2002  
OFFICE OF PETITIONS